

Paola NisticÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9292611/publications.pdf>

Version: 2024-02-01

63
papers

2,881
citations

218592

26
h-index

175177

52
g-index

69
all docs

69
docs citations

69
times ranked

4252
citing authors

#	ARTICLE	IF	CITATIONS
1	Actin Cytoskeleton and Regulation of TGF β ² Signaling: Exploring Their Links. <i>Biomolecules</i> , 2021, 11, 336.	1.8	17
2	Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 102.	3.5	64
3	Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. <i>Biology</i> , 2021, 10, 913.	1.3	2
4	A cytofluorimetric assay to evaluate T cell polyfunctionality. <i>Methods in Enzymology</i> , 2020, 631, 61-76.	0.4	0
5	Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	6.0	217
6	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 89.	3.5	157
7	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020, 10, 202.	1.3	6
8	Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. <i>International Journal of Biological Markers</i> , 2020, 35, 8-11.	0.7	15
9	Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. <i>Communications Biology</i> , 2020, 3, 85.	2.0	36
10	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Na ⁺ ve/Memory T Cell Immunomonitoring. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	0.9	8
11	The actin modulator hMENA regulates GAS-AXL axis and tumor cancer/stromal cell cooperation. <i>EMBO Reports</i> , 2020, 21, e50078.	2.0	20
12	Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. <i>Journal of Translational Medicine</i> , 2019, 17, 131.	1.8	17
13	3D models in the new era of immune oncology: focus on T cells, CAF and ECM. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 117.	3.5	78
14	Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 729.	2.2	101
15	hMENA is a key regulator in endothelin-1 β -arrestin1-induced invadopodial function and metastatic process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3132-3137.	3.3	21
16	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>OncImmunology</i> , 2018, 7, e1465163.	2.1	6
17	hMENA isoforms impact NSCLC patient outcome through fibronectin/ β ¹ integrin axis. <i>Oncogene</i> , 2018, 37, 5605-5617.	2.6	17
18	IL-18 receptor marks functional CD8 ⁺ T cells in non-small cell lung cancer. <i>OncImmunology</i> , 2017, 6, e1328337.	2.1	23

#	ARTICLE	IF	CITATIONS
19	Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 16.	6.9	101
20	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 471-486.	1.1	5
21	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 67-77.	3.2	71
22	The pattern of hMENA isoforms is regulated by TGF- β 1 in pancreatic cancer and may predict patient outcome. <i>Oncolmmunology</i> , 2016, 5, e1221556.	2.1	23
23	Polyfunctional Melan-A-specific tumor-reactive CD8 ⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. <i>Oncolmmunology</i> , 2016, 5, e1114203.	2.1	25
24	hMENA ^{11a} , a hMENA isoform sending survival signals. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1083648.	0.3	2
25	hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. <i>Oncogene</i> , 2016, 35, 887-896.	2.6	13
26	Abstract A003: Polyfunctional antitumor CD8 T cells obtained from a broad repertoire elicited by chemo-immunotherapy and preventing melanoma relapse depends on the activation of an AKT pathway sustained by ICOS. , 2016, , .		0
27	Abstract A113: The pattern of hMENA isoforms is regulated by TGF- β 1 in pancreatic cancer and may predict patient outcome. , 2016, , .		0
28	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. <i>Oncogene</i> , 2015, 34, 2493-2504.	2.6	59
29	Abstract 4316: hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. , 2015, , .		1
30	Abstract A60: The hMENA Splicing Program: An important regulator of TGF β 1-driven EMT and invasiveness in pancreatic cancer. , 2015, , .		0
31	β 1 and β 4 integrins: from breast development to clinical practice. <i>Breast Cancer Research</i> , 2014, 16, 459.	2.2	57
32	hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?. <i>Journal of Translational Medicine</i> , 2014, 12, .	1.8	0
33	Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , 2014, 5, 11054-11063.	0.8	32
34	Abstract 1035: hMENA splicing program and TGF- β 1-mediated EMT in pancreatic cancer. , 2014, , .		0
35	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , 2013, 6, 67.	6.9	42
36	Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19280-19285.	3.3	112

#	ARTICLE	IF	CITATIONS
37	Molecular and Genetic Bases of Pancreatic Cancer. <i>Current Drug Targets</i> , 2012, 13, 731-743.	1.0	24
38	Epithelial-Mesenchymal Transition: General Principles and Pathological Relevance with Special Emphasis on the Role of Matrix Metalloproteinases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a011908-a011908.	2.3	231
39	Abstract 4406: Clinical efficacious combined chemo/immunotherapy differently activates AKT pathway and functionality of gp100 and Melan-A specific T cell clones. , 2012, , .		0
40	Circulating Autoantibodies to Phosphorylated β -Enolase are a Hallmark of Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 105-112.	1.8	119
41	Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients. <i>Cancer Research</i> , 2010, 70, 7084-7092.	0.4	57
42	The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer. <i>PLoS ONE</i> , 2010, 5, e15852.	1.1	23
43	Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model.. <i>Journal of Clinical Oncology</i> , 2010, 28, 7027-7027.	0.8	1
44	Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. <i>International Journal of Cancer</i> , 2009, 124, 130-139.	2.3	103
45	An integrated humoral and cellular response is elicited in pancreatic cancer by β -enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. <i>International Journal of Cancer</i> , 2009, 125, 639-648.	2.3	115
46	Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 153-159.	1.7	107
47	Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. <i>Journal of Translational Medicine</i> , 2009, 7, 21.	1.8	32
48	Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. <i>Clinical Cancer Research</i> , 2008, 14, 4943-4950.	3.2	63
49	Imaging laser diffractometer for traceable grating pitch calibration. <i>Measurement Science and Technology</i> , 2007, 18, 375-383.	1.4	22
50	Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena+11a Phosphorylation in Breast Cancer Cell Lines. <i>Cancer Research</i> , 2007, 67, 2657-2665.	0.4	80
51	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. <i>Journal of Proteome Research</i> , 2007, 6, 4025-4031.	1.8	88
52	The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2-Positive/Hormonal Receptor-Negative Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 1470-1478.	3.2	73
53	Human mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+T-cell immune response. <i>International Journal of Cancer</i> , 2004, 109, 909-918.	2.3	78
54	Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer. <i>Journal of Immunotherapy</i> , 2001, 24, 221-231.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. <i>International Journal of Cancer</i> , 1999, 84, 598-603.	2.3	12
56	Low Frequency of ErbB-2 Proto-oncogene Overexpression in Human Leukocyte Antigen-A2-Positive Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 1997, 89, 319-321.	3.0	13
57	MHC-Peptide Binding. <i>Journal of Immunotherapy</i> , 1997, 20, 431-436.	1.2	8
58	Melan-A/MART-1 Antigen Expression in Cutaneous and Ocular Melanomas. <i>Journal of Immunotherapy</i> , 1997, 20, 466-469.	1.2	15
59	$\hat{1}\pm 6\hat{1}^{24}$ and $\hat{1}\pm 6\hat{1}^{21}$ Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines. <i>Experimental Cell Research</i> , 1997, 236, 76-85.	1.2	201
60	Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.. <i>Journal of Clinical Investigation</i> , 1994, 94, 1426-1431.	3.9	9
61	Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.. <i>Journal of Clinical Investigation</i> , 1992, 90, 1093-1099.	3.9	15
62	Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. <i>International Journal of Cancer</i> , 1990, 46, 539-545.	2.3	24
63	Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 2941-2945.	3.3	20